ENDPOINTS

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

As it awaits an FDA approval decision, Scholar Rock is reshaping its leadership team with industry veterans. Current CEO Jay Backstrom is departing the Cambridge, MA-based drug developer in a "planned transition." David Hallal, who ...

Apr 28, 2025 - 16:00
 0
Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild
As it awaits an FDA approval decision, Scholar Rock is reshaping its leadership team with industry veterans. Current CEO Jay Backstrom is departing the Cambridge, MA-based drug developer in a "planned transition." David Hallal, who ...
Read More

Tags:

Previous Article

Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe

Next Article

What Happens When US Electricity Demand Craters?

Related Posts

Veraxa makes a SPAC deal; Illumina discloses layoffs

Veraxa makes a SPAC deal; Illumina discloses layoffs

Apr 23, 2025  0

AbbVie eyes $10B US expansion amid sector-specific tariff threat

AbbVie eyes $10B US expansion amid sector-specific tari...

Apr 25, 2025  0

Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold

Merck cuts several Phase 2 programs; Vyne’s Phase 1b ps...

Apr 25, 2025  0